It seemed to many that the provider of new drugs to lose weight was a wish that had come true for them after waiting for decades or years. The “Wegovi” and “Ozimbek” and “Mongaro” drugs succeeded in getting rid of between 15% and 20% of their weight, or about 27 kilograms for a person who weighed 136 kilograms. This was not possible before. However, some doctors, psychiatrists and eating disorder experts worry that these new drugs, originally designed to treat diabetes, may eventually become a problem. They point out that its confirmed side complications include nausea, diarrhea, vomiting, and constipation. One study says that half of all diabetic patients give up a new generation of diabetes medications just a year after its onset. And the percentage reaches 70% for those who abandon the new drug within two years of taking it. Also, the failure of these people to continue using these new drugs for life will lead to the return of sagging and obesity. Psychologists say that this relapse has a negative psychological impact on these patients. In addition, those who lose weight by taking these new drugs, which are given with a needle weekly, still have to exercise, and take care to follow a specific diet to ensure that the desired benefit is achieved from these drugs. While scientists insist that a significant decrease in weight depends on the improvement of the individual's health; However, these new drugs have not yet been proven to improve the general health of their users. Patients do not want to believe or imagine – just imagine – how much the manufacturers of these drugs, which cost at least $1,000 a month, are going to convince them that they desperately need drugs to suppress their appetites. Ultimately, she wants to convince people that half the mass of an obese person is healthy, and the other half is disease. Scientists confirm that many obese people are considered in good health, compared to the diseases that affect obese people. And weight-loss drugs don't make sense to them, because they are, in fact, healthy. There are thin people who suffer from high blood pressure. There are obese people who doctors consider overweight, but they do not suffer from any disease. And the American newspaper "USA Today" quoted a professor at Jugtown University, Dr. Adrienne Fogh-Berman, as saying that it is not very clear that there are good health outcomes for taking weight loss drugs. Tigress Osborne, Chair of the Board of Directors of the American National Association for the Promotion of Obesity Acceptance, said that with the advent of every new drug to reduce weight, the social focus is on turning the obese into thin people… as if the world had no problem except to turn the obese into thin and emaciated people. Pharmaceutical companies, especially the Danish company Novo Nordisk – maker of the drug "Wegovi" and "Ozimbek" – have been making intensive efforts for years to encourage demand for their aforementioned medicines. The company paid about $14 million in 2021 to train doctors and teach them the benefits of the two drugs. Eli Lilly, the US pharmaceutical company, spent less than $1 million in this area to encourage demand for Monjaro, which it invented, for weight loss. Novo Nordisk's brand manager, Natalia Salomao, said her company believes "responsible interaction" between pharmaceutical companies and the physician community is good for patients, and encourages care and science. She added that obesity is a chronic, progressive and incomprehensible disease that requires long-term drug management. She added that there is a widespread belief that obesity is a disease in which one falls by choice, while the truth is that it is a disease caused by biological factors that prevent those affected from losing weight and staying in this state. British health authorities recently suspended Novo Nordisk for two years from participating in pharmaceutical lobbying in the UK, after it sponsored a training program that British authorities judged did not appear to be a paid "roadshow". It was the eighth time in 40 years that the Confederation of the British Pharmaceutical Industry has sanctioned a company that is a member of it. The company is also making similar efforts to convince health insurance companies to agree to cover weight-loss drugs. A study published recently by the American New England Journal of Medicine stated that covering only 20% of obese people would cost government health insurance $13 billion annually.
What you should know before taking "Wegovi" and "Ozimbek"
With the adherence of scientists and doctors that weight loss drugs, especially “Wegovi” and “Ozimbek”, are not for everyone. As it is intended for those whose body mass index exceeds 30, or whose weight mass index exceeds 27 if they suffer from chronic diseases, or type 2 diabetes. Before taking this class of drugs, which are based on the “simaglutide” compound, many important considerations must be studied, such as lifestyle, potential side complications, treatment plan, and the future of treatment in the long term. American endocrinologist and obesity consultant Dr. Scott Isaacs told the American "Insider" website that semaglutide can be very beneficial for people who have tried several means to lose weight. However, obesity is not a matter of will, but of hormones and human biology. However, Semaglutide is not a substitute for healthy habits. In many cases, you must practice other strategies to reduce weight before taking modern drugs. Even those who have succeeded in reducing their weight with semaglutide drugs, good nutrition and physical activity are indispensable to maintain good health for as long as possible. Internal medicine consultant Dr. Christopher Kakgwan pointed out that the negative complications of anti-obesity drugs often occur during the first period after taking these drugs. In addition to diarrhea, constipation, nausea and vomiting, others experienced a loss of appetite. It became difficult for many of them to eat the foods they used to devour, especially foods sweetened with sugar and foods fried in oil.
Pharmaceutical company Vaking Therapeutics announced that experiments on a drug developed by its scientists to treat obesity have proven to be safe and effective in reducing weight by up to 6%, according to data from the first phase of the studies. The company will start the second phase of its experiments in mid-2023. It hopes that its new drug will compete with other companies, such as the Danish Novo Nordisk. The initial trial included 88 volunteers. The company plans to give some volunteers a larger trial dose over a longer period of time. The second phase of the trials will also include administering oral doses of the new drug for a period of 28 days, in order to accurately determine its effectiveness and safety. Results are expected to appear during the second half of the current year.
US states seeking to ban cosmetics!
A number of US state legislatures are considering passing legislation to ban certain cosmetic products that contain harmful chemicals known as PFAS. The Vermont State Congress passed a law banning manufacturers and suppliers from selling and distributing any cosmetic or menstrual materials that contain PFOA and PFOA, among a number of other chemicals. Prohibited items include shampoo, deodorant, and hair dye. And the states of California, Colorado, and Maryland have approved similar legislation, which will take effect from 2025. The US Environmental Protection Agency indicated that several studies confirmed that these chemicals cause cancer, delay children’s growth, damage the liver and thyroid gland, increase cholesterol, and reduce the effectiveness of The immune system, especially in young children. The two aforementioned substances are known to remain forever in the environment. Legislation being considered by Congress in the state of Forment includes adding a number of other consumer items to the ban, including raincoats, synthetic turf, snowboarding clothing and even sheets that contain PFAS chemicals. And the Environmental Protection Agency proposed last March to ban the use of these chemical compounds in drinking water, stressing that this would save thousands of lives from cancer. These compounds have been used since the 1940s in a large number of consumer goods, such as non-stick pans, food preservation containers, and firefighting foam. A study conducted by the University of Notre Dame in 2021 indicated that more than half of the number of cosmetics sold in America and Canada contain these toxic substances. Notre Dame researchers studied about 230 products that are frequently used every day, and discovered that they are present in 56% of eye cosmetics, and 48% of lip products.
Okaz (London, Washington) @OKAZ_online
